Novo Nordisk Obesity Trial Results
This is a news story, published by Yahoo Finance, that relates primarily to Novo Nordisk news.
Novo Nordisk news
For more Novo Nordisk news, you can click here:
more Novo Nordisk newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
experimental obesity pill monlunabant. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Canadian biotech company Inversago Pharmaceuticals news, weight loss news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Novo NordiskReuters
•Novo Nordisk shares drop more than 4% on disappointing obesity pill data
76% Informative
Danish drugmaker Novo Nordisk shares fell more than 4% on Friday to their lowest level since Aug. 10 .
Results from a Phase 2a trial of its experimental obesity pill monlunabant came in below market expectations.
The once- daily pill resulted in only 6.5% weight loss after 16 weeks .
VR Score
88
Informative language
97
Neutral language
2
Article tone
formal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links